HERTFORDSHIRE, England and
PITTSBURGH, Dec. 1, 2016 /PRNewswire/ -- Today, Mylan
N.V. (NASDAQ, TASE: MYL) joins people worldwide in recognizing
World AIDS Day. Observed every Dec.
1, the occasion represents an opportunity to support people
living with HIV/AIDS and to remember the approximately 35 million
who have died from AIDS-related illnesses since the epidemic
began.
Mylan always has been committed to providing people with access
to more affordable medicines, and years ago made a commitment to
stem the tide of HIV/AIDS by bringing to bear its ability to
innovate, commitment to quality and growing manufacturing scale to
help the people who most need it, no matter where they are or who
they are.
"At Mylan, we view every day of every year as an opportunity to
stem the disease's tide," commented Mylan CEO Heather Bresch. "Mylan's ARV products now are
used by approximately half of everyone on the planet who is
receiving treatment for HIV/AIDS. So it's important that we
continue to invest and to leverage the millions of dollars we
already have invested over the past several years to scale up our
portfolio and ARV manufacturing capacities."
Mylan is one of the world's leading providers of HIV/AIDS
medicines and strives to meet global demand with a reliable supply
of affordable medications. Its portfolio currently contains 16
active pharmaceutical ingredients (API) and 50 finished dosage
forms. Mylan continues to invest in R&D and operations to keep
pace and stay ahead in providing the comprehensive basket of
vertically integrated and affordable quality drug products for the
future.
"Mylan has a long tradition of innovation, and we're not
standing still," said Mylan President Rajiv
Malik. "We have more than 3,000 scientists worldwide, many
of them dedicated to our ARV franchise, working to develop
innovative solutions to satisfy unmet needs. Their skill and
dedication allowed us to submit an application in March 2016 to the U.S. Food and Drug
Administration for a reduced-dose version of the world's most
commonly used ARV combination drug, Tenofovir Disoproxil Fumarate +
Lamivudine + Efavirenz."
Mylan's version, which uses one-third less Efavirenz, is
formulated to be as effective as the original version. If approved,
the company believes it will improve the side effect profile and
also will save payers money by requiring less API in each tablet, a
meaningful change for a product now used by more than 5.5 million
people each year.
Over the next twelve months, Mylan expects to submit several
more applications for innovative ARVs that will help push down
costs while continuing to improve patients' well-being.
Mylan also continues to build on its highly successful and
important work over the years in serving "access markets." These
markets comprise approximately 100 developing countries in which
brand producers of ARVs license or otherwise permit competition by
generics to help make sure these more affordable alternatives are
available to people with limited incomes. Specifically, Mylan now
is bringing its passion for meeting unmet needs to middle- and
higher-income markets as well, including the U.S. and Europe.
Mylan encourages everyone to observe World AIDS Day and make a
commitment to address the scourge of HIV/AIDS. There are many ways
to help. One place to start is by learning more about the disease,
including its routes of transmission. Organizations such as UNAIDS
and the World Health Organization are great resources people can
use to learn and share information with family, friends or
neighbors.
Mylan is a global pharmaceutical company committed to setting
new standards in healthcare. Working together around the world to
provide 7 billion people access to high quality medicine, we
innovate to satisfy unmet needs; make reliability and service
excellence a habit; do what's right, not what's easy; and impact
the future through passionate global leadership. We offer a growing
portfolio of more than 2,700 generic and branded pharmaceuticals,
including antiretroviral therapies on which approximately 50% of
people being treated for HIV/AIDS worldwide depend. We market our
products in more than 165 countries and territories. Our global
R&D and manufacturing platform includes more than 50
facilities, and we are one of the world's largest producers of
active pharmaceutical ingredients. Every member of our more than
40,000-strong workforce is dedicated to creating better health for
a better world, one person at a time. Learn more at mylan.com.
This press release includes statements that constitute
"forward-looking statements," including with regard to product
submissions and expectations, markets for products, investments,
product capacity, and Mylan's strategy. These statements are
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Because such
statements inherently involve risks and uncertainties, actual
future results may differ materially from those expressed or
implied by such forward-looking statements. Factors that
could cause or contribute to such differences include, but are not
limited to: any changes in or difficulties with Mylan's or
its partners' ability to develop, manufacture, and commercialize
products; any regulatory, legal, or other impediments to Mylan's or
its partners' ability to bring products to market; changes in the
economic and financial conditions of the businesses of Mylan or its
partners; the scope, timing, and outcome of any ongoing legal
proceedings and the impact of any such proceedings on Mylan's or
its partners' business; actions and decisions of healthcare and
pharmaceutical regulators, and changes in healthcare and
pharmaceutical laws and regulations, in the United States and abroad; risks associated
with international operations; other uncertainties and matters
beyond the control of management; and the other risks detailed in
Mylan's filings with the Securities and Exchange Commission. Mylan
undertakes no obligation to update these statements for revisions
or changes after the date of this release.
Logo - http://photos.prnewswire.com/prnh/20140423/77793
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mylans-commitment-to-stemming-the-tide-of-hivaids-as-strong-as-ever-300371407.html
SOURCE Mylan N.V.